Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Joseph Haas
Already a significant investor in the health care technology firm, buyout will give Roche access to substantial real-world cancer development data. Astellas acquires stem cell-focused Universal Cells.
Emerging Company Profile: Where other microbiome-focused firms seek to add bacteria to the patient's gut, Israel's BiomX thinks it can treat IBD and other conditions with phage therapies that subtract harmful microbiota.
A new report released during the BIO CEO conference shows novel pain therapy candidates face a high failure rate, which may help explain why smaller, privately held biotechs aren't very active in the space.